Breast cancer: FDA approves new treatment, Enhertu, for patients with HER2-positive breast cancer
by Press Release from Outbreak News Today on (#4WXJ5)
The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Enhertu ["]
The post Breast cancer: FDA approves new treatment, Enhertu, for patients with HER2-positive breast cancer appeared first on Outbreak News Today.